Skip Navigation
Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​
NIH HHS News Release Logo

National Institute of Allergy and
Infectious Diseases (NIAID)
http://www.niaid.nih.gov

FOR IMMEDIATE RELEASE
Tuesday, Aug. 18, 1998

Media Contact:
Patricia Randall
(301) 402-1663

niaidnews@niaid.nih.gov

Skip Content Marketing
  • Share this:
  • submit to facebook
  • Tweet it
  • submit to reddit
  • submit to StumbleUpon
  • submit to Google +

NIAID Collaborates with VaxGen on Vaccine Studies

As part of its broad-based HIV/AIDS vaccine research efforts, the National Institute of Allergy and Infectious Diseases (NIAID) will collaborate with VaxGen, Inc., in research projects to be done in conjunction with the company’s current Phase III AIDS vaccine studies.

The collaboration will entail research – in addition to that currently called for in VaxGen’s trial plans – on immune responses induced by AIDSVAX, as well as use of AIDSVAX in combination with other vaccines currently being studied by NIAID. Additional joint research aimed toward creating formulations of AIDSVAX for viruses prevalent in developing nations is also under discussion.

"The effort to develop a safe and effective vaccine against HIV/AIDS is a global imperative and the highest priority of the NIH AIDS research program," says Anthony S. Fauci, M.D., NIAID director. "We expect this collaboration with VaxGen to take us closer to our mutual goal."

In June, VaxGen began its trial of AIDSVAX. AIDSVAX has been shown to be safe and to stimulate antibody production. The three-year study is the first large-scale trial of an HIV preventive vaccine and will involve 5,000 volunteers at about 40 clinical sites in North America. VaxGen is sponsoring these trials and anticipates conducting additional Phase III studies in Thailand.

NIAID is also studying other vaccine designs aimed at stimulating different components of the immune system. These activities are part of NIAID’s ongoing efforts to determine systematically the effects of immunization and the potential for different approaches to prevent HIV disease.

VaxGen, Inc., based in South San Francisco, Calif., is a biotechnology company committed to making an HIV vaccine for worldwide use.


NIAID conducts and supports research—at NIH, throughout the United States, and worldwide—to study the causes of infectious and immune-mediated diseases, and to develop better means of preventing, diagnosing and treating these illnesses. News releases, fact sheets and other NIAID-related materials are available on the NIAID Web site at www.niaid.nih.gov.

About the National Institutes of Health (NIH): NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit www.nih.gov.

NIH...Turning Discovery Into Health ®

back to top


Archive

NIAID Archive

Important note: Information on this page was accurate at the time of publication. This page is no longer being updated.
​​​​

Last Updated August 18, 1998